<DOC>
	<DOCNO>NCT01433432</DOCNO>
	<brief_summary>The open label extension study ( Protocol C2/13/DR-6MP-02 EXT ) design evaluate clinical efficacy safety 80 mg DR-6MP test formulation additional 12 week subject already complete 12 week Protocol C2/13/DR-6MP-02 . Crohn 's disease ( CD ) therapy aim reduce inflammation via induction remission flare-up maintenance remission long possible . The question ask extension study : 1 . For subject receive 80 mg DR-6MP 12 week : Can clinical efficacy safety status achieve follow 12 week treatment maintain improved following additional 12 week DR-6MP treatment ? 2 . For subject receive oral Purinethol ( 1-1.5 mg/kg daily ) 12 week : Can clinical efficacy safety 12 week maintain improved following introduction 12 week 80 mg DR-6MP treatment ?</brief_summary>
	<brief_title>Open Label Extension Study Protocol C2/13/DR-6MP-02</brief_title>
	<detailed_description>By follow 2 group subject , i.e , originally receive test formulation ( 80 mg DR-6MP ) continue another 12 week test drug vs. receive reference drug ( Purinethol , 1-1.5 mg/kg daily ) introduce 12 week 80 mg DR6MP test drug , monitor CDAI score , immunology parameter ( ex . ESR CRP ) safety assessment ( i.e. , adverse event occurrence , weight change , laboratory test result ) compare parameter extension study start , study effectively answer follow question : 1 . Does additional 12 week 80 mg DR6MP test drug treatment maintain improve CDAI score ? 2 . Is additional 12 week 80 mg DR6MP test drug treatment safer due negligible drug availability systemically ? 3 . Can additional 12 week 80 mg DR6MP test drug treatment evoke effective immunological systemic response ? 4 . In subset subject willing undergo colonoscopy/ileoscopy , additional 12 week 80 mg DR6MP test drug induce effective mucosal heal ?</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>1 . Male ( nonpregnant ) female subject , complete Protocol C2/13/DR6MP02 , age 1875 year ( inclusive ) serious adverse event complication consent PI 2 . Study entry screen laboratory test must meet following criterion : WBC great equal 3000mm3 ALT , AST le 2 x upper limit normal Total direct bilirubin le 2 x upper limit normal Note : induction study Protocol C2/13/DR6MP02 Week 12 termination lab serve screen lab extension study provide subject enters extension study within 2 week complete induction study . If interval longer , however , repeat screen lab must conduct . 3 . Subjects must agree take treatment Crohn 's disease stable dose 5ASA , chronic antibiotic lowdose oral steroid ( prednisolone 15 mg daily ; budesonide 6 mg daily ) extension study entry throughout study . 4 . Subjects willing able provide write informed consent . 1 . Subjects body weight extension study entry 42.5 kg 2 . Women pregnant nursing time extension study entry intend study period 3 . Women childbearing potential practice acceptable method birth control [ acceptable method birth control : surgical sterilization , intrauterine device , oral contraceptive , contraceptive patch , longacting injectable contraceptive , partner 's vasectomy , doubleprotection method ( condom diaphragm spermicide ) abstinence ] 4 . Subjects plan elective surgery hospitalization course study ( may interfere study compliance outcome ) 5 . Subjects unavailable duration trial , unable comply plan schedule study visit , likely noncompliant protocol , felt unsuitable investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Crohn 's Disease</keyword>
</DOC>